TCGA-CN-4728-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.490
- MYOGENESIS+0.470
- COAGULATION+0.460
- HEDGEHOG_SIGNALING+0.430
- KRAS_SIGNALING_UP+0.410
- IL2_STAT5_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.370
- COMPLEMENT+0.340
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.590
- MYC_TARGETS_V1-0.580
- G2M_CHECKPOINT-0.500
- OXIDATIVE_PHOSPHORYLATION-0.460
- DNA_REPAIR-0.440
- MTORC1_SIGNALING-0.360
- GLYCOLYSIS-0.280
- FATTY_ACID_METABOLISM-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.964 |
| 2 | TCGA-CN-5358-01A-01R-1514-07 | — | — | 0.944 |
| 3 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.937 |
| 4 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.934 |
| 5 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.932 |
| 6 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.927 |
| 7 | C3N-02237 | — | cohortA1 | 0.927 |
| 8 | TCGA-56-A4ZJ-01A-11R-A262-07 | — | cohortSQ1 | 0.925 |
| 9 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.924 |
| 10 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.470 | Inavolisib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |